24th Jul 2007 08:18
Tarsus Group PLC24 July 2007 24 July 2007 Tarsus Group PLC CapRegen plc - Admission to AIM Tarsus Group plc (LSE: TRS) ('Tarsus'), the international media group withinterests in exhibitions, conferences, publishing and online media, is delightedto announce that CapRegen plc ('CapRegen') has been admitted to AIM aftersuccessfully raising £3.2 million, before expenses, by way of a placing withinstitutional and other investors at a placing price of 5p per Ordinary Share of1p each (the 'Placing Price'), valuing the CapRegen's issued ordinary sharecapital at £4,450,500 on Admission. Following the placing, Tarsus has a beneficial ownership of 15,500,000 OrdinaryShares in CapRegen (worth £775,000 at the Placing Price), representing 17.4% ofCapRegen's enlarged issued share capital. CapRegen is a newly incorporated public limited company that has beenestablished in order to make investments in the global anti-ageing andregenerative medicine market place. CapRegen will use the expertise of Dr RobertGoldman, PhD, DO, FAASP and Dr Ronald Klatz., D.O. to invest in medicaltechnologies that they and the other Directors believe have commercialviability. Dealings in CapRegen's shares commenced as of 8.00am today, 24 July 2007 underthe ticker symbol CGN. Further information about CapRegen's is available in itsannouncement released today. Douglas Emslie, Group Managing Director of Tarsus Group plc and Chairman,CapRegen plc said: "CapRegen's IPO is an exciting development for Tarsus and follows theacquisition of MCII which owns and operates the three leading medical sectorexhibitions and conferences in the US anti-ageing market. MCII's first majormedical event of the year in Orlando was significantly ahead of the prior yearwith revenues up 112%. "Tarsus now has extensive knowledge of the anti-ageing market and CapRegenbrings together specific healthcare and investment expertise to capitalise onopportunities in this fast growing sector. With a number of potential investeecompanies already available to the company, CapRegen is in an extremely strongposition to generate exciting returns for its shareholders." Enquiries:Tarsus Group plc 020 8846 2700Doug Emslie, Group Managing Director Madano Partnership 020 7593 4000Mark Way / Matthew Moth IR Focus 020 7593 4000Neville Harris This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Tarsus